RFA Effective for Single, Small Hepatocellular Carcinoma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 5
Volume 15
Issue 5

The minimally invasive procedure of radiofrequency ablation (RFA) appears to be as effective as surgical resection for the treatment of patients with a small hepatocellular carcinoma (HCC) and offers similar survival, according to a study presented at the 31st Annual Meeting of the Society of Interventional Radiology (abstract 1021). "Radiofrequency ablation can offer the same life expectancy as surgical resection to patients with solitary, small HCC, most of whom cannot tolerate a resection," said Riccardo Lencioni, MD, University of Pisa, Italy.

TORONTO, Ontario—The minimally invasive procedure of radiofrequency ablation (RFA) appears to be as effective as surgical resection for the treatment of patients with a small hepatocellular carcinoma (HCC) and offers similar survival, according to a study presented at the 31st Annual Meeting of the Society of Interventional Radiology (abstract 1021). "Radiofrequency ablation can offer the same life expectancy as surgical resection to patients with solitary, small HCC, most of whom cannot tolerate a resection," said Riccardo Lencioni, MD, University of Pisa, Italy.

Dr. Lencioni noted that oncologists have one advantage with HCC: "We know who will develop the tumor. The population at risk is clearly identified," he said. Because of this, people with chronic liver disease, such as hepatitis or cirrhosis, generally undergo screening every 6 months or so. The downside is that this is a very difficult population to treat, he said. Surgical resection has been the first choice, but in some patients, removing a tumor along with some surrounding tissue leads to a drop in liver function. "While the tumor may be removed, what's left behind isn't healthy tissue. This is why this type of early-diagnosis surgical resection cannot be performed safely in about 90% of patients," he said.

Dr. Lencioni pointed out that although HCC has historically mostly affected people living in Asian and Southern European countries, "the incidence is rising every year, even in North America, particularly in the United States, because of the dissemination of hepatitis C virus infections. Increasing numbers of patients got the infection in past years, and now they are developing the tumor."

The investigators searched the Tumor Radiofrequency Ablation Italian Network (TRAIN), which contains data on more than 1,000 HCC patients across Italy, for patients with a uninodular HCC of 5 cm or less with no portal vein invasion or extraheptic spread and Child-Pugh class A cirrhosis, who underwent either surgical resection (38 patients) or RFA (124 patients). Patients were matched for age, tumor size, date of diagnosis, and AFP (alpha-fetoprotein) level. RFA was performed under ultrasound guidance using the RITA Medical device.

Three-year overall survival was similar between the RFA (71.8%) and resection groups (65.1%) (P = .1631). "We were really very impressed to see that ablation achieved the same results as surgery," he said. Tumor recurrence rates were also similar: 55.2% for RFA and 58.5% for resection. With respect to local tumor progression, RFA was not as effective as resection. "Local relapse was 0% for resection and 19.3% for RFA, but this is something we can manage with repeat RFA," Dr. Lencioni said. Because patients come in for frequent follow-up, repeat RFA is not difficult to schedule. RFA is easier to perform than surgery and is not accompanied by the same risks and morbidities, he said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content